MRK · News · 20261030N
Guidance and Outlook
Merck & Co., Inc. · 2026-10-30 · Importance 40 · Surprise 42
Management raised Merck’s full-year 2026 sales and earnings outlook, but the report does not provide the revised forecast amounts. Executives cited generic competition and vaccine-market pressures as factors that could temper growth in 2027. Rising research expenditures were also identified as a potential constraint on 2027 growth as Merck develops a portfolio to support growth beyond KEYTRUDA’s loss of exclusivity.